Elizabeth Rozek - 19 Feb 2026 Form 4 Insider Report for Sagimet Biosciences Inc. (SGMT)

Reporting relationship: Chief Legal & Admin. Officer
Issuer ticker: SGMT
Reported as of: 19 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Feb 2026, 16:43:57 UTC
Prior SEC filing: 12 Feb 2026
Next SEC filing: 01 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Elizabeth Rozek

Key filing fact

Elizabeth Rozek filed Form 4 for Sagimet Biosciences Inc. (SGMT) on 20 Feb 2026.

Key facts

This page summarizes Elizabeth Rozek's Form 4 filing for Sagimet Biosciences Inc. (SGMT).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 20 Feb 2026, 16:43.

Change

Previous filing in this sequence was filed on 12 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001975022 Primary reporting owner

Rozek Elizabeth

Relationship: Chief Legal & Admin. Officer
Address: SAGIMET BIOSCIENCES INC., 155 BOVET ROAD, SUITE 303, SAN MATEO
Signature: /s/ Elizabeth Rozek
Signature date: 20 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SGMT transaction

Series A Common Stock

Award

Transaction value: $0
Shares: +44,000
Change %: +23%
Price: $0.000000
Shares after: 234,959
Date: 19 Feb 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SGMT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +88,000
Change %
Price: $0.000000
Shares after: 88,000
Date: 19 Feb 2026
Ownership: Direct
Underlying class: Series A Common Stock
Underlying amount: 88,000
Exercise price: $5.38
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date.

Footnote F2

The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date.